What is the most recent earnings date for CTMX stock?
CYTOMX THERAPEUTICS INC (CTMX) last reported earnings on 3/16/2026.
CYTOMX THERAPEUTICS INC (CTMX) Earnings History & Surprises
NASDAQ:CTMX • US23284F1057
Current stock price
4.52 USD
+0.1 (+2.26%)
At close:
4.52 USD
0 (0%)
After Hours:
CTMX Earnings overview
Past quarterly earnings results for CYTOMX THERAPEUTICS INC (CTMX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.13
- Revenue Estimate
- 4.765M
Last Reported
Most Recent- Release Date
- Mar 16, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.22
- EPS Surprise
- -130.26%
- Revenue Surprise
- -91.77%
Beat Rate
Last 8 Quarters 75%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.22 | -0.10 | -130.26% | -195.65% | 663K | 8.058M | -91.77% | -98.26% |
| Q3 2025 | -0.09 | -0.05 | -74.27% | -228.57% | 5.963M | 11.858M | -49.71% | -82.16% |
| Q2 2025 | 0.00 | -0.08 | 98.72% | 98.75% | 18.658M | 15.076M | 23.76% | -25.71% |
| Q1 2025 | 0.27 | 0.13 | 113.47% | 58.82% | 50.917M | 31.455M | 61.87% | 22.80% |
| Q4 2024 | 0.23 | -0.20 | 215.22% | 2,200.00% | 38.093M | 19.805M | 92.34% | 43.17% |
| Q3 2024 | 0.07 | -0.18 | 139.87% | 75.00% | 33.432M | 17.865M | 87.14% | 26.71% |
| Q2 2024 | -0.08 | -0.15 | 45.28% | -300.00% | 25.115M | 20.395M | 23.14% | 1.58% |
| Q1 2024 | 0.17 | -0.08 | 301.22% | 440.00% | 41.463M | 21.863M | 89.65% | 76.45% |
| Q4 2023 | 0.01 | -0.03 | 134.32% | 102.33% | 26.607M | 21.464M | 23.96% | 2,700.74% |
| Q3 2023 | 0.04 | -0.19 | 120.76% | 111.43% | 26.384M | 14.424M | 82.92% | 136.63% |
| Q2 2023 | -0.02 | -0.21 | 90.44% | 94.59% | 24.724M | 14.159M | 74.62% | 92.40% |
| Q1 2023 | -0.05 | -0.11 | 53.65% | 86.49% | 23.499M | 19.98M | 17.61% | 159.94% |
| Q4 2022 | -0.43 | -0.24 | -78.96% | -7.50% | 950K | 18.204M | -94.78% | 107.58% |
| Q3 2022 | -0.35 | -0.31 | -12.30% | - | 11.15M | 18.516M | -39.78% | -36.61% |
| Q2 2022 | -0.37 | -0.37 | -0.76% | -23.33% | 12.85M | 18.259M | -29.62% | -21.12% |
| Q1 2022 | -0.37 | -0.37 | 0.16% | -42.31% | 9.04M | 21.077M | -57.11% | -43.39% |
| Q4 2021 | -0.40 | -0.29 | -38.95% | -25.00% | -12.53M | 25.003M | -150.11% | -176.54% |
| Q3 2021 | -0.35 | -0.32 | -9.80% | -9.37% | 17.59M | 18.446M | -4.64% | -1.12% |
| Q2 2021 | -0.30 | -0.33 | 7.88% | 11.76% | 16.29M | 17.202M | -5.30% | -1.93% |
| Q1 2021 | -0.26 | -0.35 | 26.29% | -200.00% | 15.97M | 15.735M | 1.49% | -67.80% |
| Q4 2020 | -0.32 | -0.51 | 37.70% | - | 16.37M | 15.718M | 4.15% | - |
| Q3 2020 | -0.32 | -0.49 | 34.13% | - | 17.79M | 16.67M | 6.72% | - |
| Q2 2020 | -0.34 | 0.16 | -313.13% | - | 16.61M | 49.174M | -66.22% | - |
| Q1 2020 | 0.26 | -0.47 | 155.29% | - | 49.59M | 20.276M | 144.57% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
1.91%
Max EPS beat (4)
113.47%
Min EPS beat (4)
-130.26%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-13.96%
Max Revenue beat (4)
61.87%
Min Revenue beat (4)
-91.77%
Analysis
In the last 4 quarters, CTMX has beaten EPS estimates in 2 out of 4 releases
CTMX has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, CTMX has beaten the EPS estimates by 1.9% on average.
In the last 4 quarters, CTMX reported -14.0% below the revenue estimates on average.
Related analysis
CYTOMX THERAPEUTICS INC / CTMX Earnings FAQ
Did CTMX stock beat earnings estimates in the most recent quarter?
CYTOMX THERAPEUTICS INC (CTMX) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does CTMX stock beat earnings estimates?
In the last 4 quarters, CYTOMX THERAPEUTICS INC (CTMX) has beaten EPS estimates in 2 out of 4 releases.